BriaCell Therapeutics Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA1079301091
CAD
17.14
13.04 (318.05%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Rapid Dose Therapeutics Corp.
Avicanna, Inc.
Microbix Biosystems, Inc.
Ceapro, Inc.
Oncolytics Biotech, Inc.
Cardiol Therapeutics, Inc.
FSD Pharma, Inc.
Medicenna Therapeutics Corp.
Sernova Corp.
BriaCell Therapeutics Corp.
Cognetivity Neurosciences Ltd.
Why is BriaCell Therapeutics Corp. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is BriaCell Therapeutics Corp. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
BriaCell Therapeutics Corp.
-100.0%
0.01
1916.67%
S&P/TSX 60
19.1%
1.54
14.62%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-230.46%
EBIT to Interest (avg)
-18.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.42%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.81
EV to EBIT
-0.41
EV to EBITDA
-0.41
EV to Capital Employed
-13.87
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-200.30%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(HY)

Higher at CAD -19.04 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-6What is not working for the Company
INTEREST(9M)

At CAD 0.05 MM has Grown at inf%

ROCE(HY)

Lowest at -608.22%

Here's what is working for BriaCell Therapeutics Corp.
Net Profit
Higher at CAD -19.04 MM
than preceding 12 month period ended Apr 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CAD MM)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for BriaCell Therapeutics Corp.
Interest
At CAD 0.05 MM has Grown at inf%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)